Clinical Trial Search

Primary: Alcohol Craving in Response to the Alcohol Cue Script — 12.7; 10.7 Units on a scale

Primary: Radiographic Response — 27.8 percentage of participants

Primary: Change From Baseline in Target Area Hair Count (TAHC) — 131.3; 140.4; 129.0; 9.3 terminal hairs/cm2

Primary: Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline)…

Primary: Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline)…

Primary: Number of Patients With a Partial Response, Progressive Disease, or Stable Disease Based on Prostate-Specific Antigen (PSA) or Measurable Disease — 7; 7; 9 participants

Primary: Cumulative CD54+ Cell Count — 1.58 10^9 cells/mL

Primary: Overall Survival — 424; 321 Days — p=0.3873

Primary: Percentage of Patients Alive and Free of Progression at 6 Months — 27 percentage of patients

Primary: Patients With Change in HVPG From Baseline — 1; 1 participants

Primary: Clearance (CL) of Carfilzomib on Day 1 of Cycle 1 — 151; 113; 288; 170 liters/hour — p=0.4114

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (DLT) — 0; 0; 1; 0 participants

Primary: Percentage of Participants With a Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR) — 75.0 percentage of participants

Primary: Maximum Tolerated Dose (MTD) of 90Y-HAT — 15 mci

Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants